슬롯사이트 inno.N’s Korea-first topical JAK-1 inhibitor for 'atopy' novel drug substance receives phase 2 approval

[by Lee, Young Sung] 슬롯사이트 inno.N announced on March 17 that it has recently received approval from the Ministry of Food and Drug Safety for the Phase 2 clinical trial plan (IND) of its JAK inhibitor autoimmune disease novel drug, ‘IN-115314.’

슬롯사이트 inno.N is developing IN-115314 as a novel treatment for patients with mild to moderate atopic dermatitis. This new autoimmune disease drug substance operates through a Janus kinase-1 (JAK-1) inhibition mechanism, targeting the inflamed area locally and selectively inhibiting only the JAK-1 enzyme. The company anticipates that this action will lead to reduced systemic absorption compared to existing treatments, potentially lowering the risk of side effects.

IN-115314 is the first 슬롯사이트 inhibitor in Korea being developed as a topical formulation (ointment), with its Phase 1 clinical trial having been completed in December 2024.

IN-115314 demonstrated superior treatment effects for atopic dermatitis compared to the control 슬롯사이트 in phase 1 clinical trials, while also confirming its safety, tolerability, and pharmacodynamic characteristics. Phase 2 clinical trials will focus on determining the appropriate dosage for adult patients with atopic dermatitis.

Atopic dermatitis is a chronic inflammatory skin condition affecting approximately 3-7% of adults worldwide. In 슬롯사이트, around 970,000 patients were treated for atopic dermatitis annually as of 2023.

Current topical treatments for atopic dermatitis include corticosteroids, calcineurin 슬롯사이트s, and PDE-4 슬롯사이트s, or they are still in development. However, these treatments have limitations, such as challenges with long-term use and the potential for discomfort like a burning sensation upon application.

The global market for the JAK inhibitor series being developed by 슬롯사이트 inno.N is experiencing rapid growth, with an average annual growth rate of approximately 17.7%. The market size is expected to increase from USD 20.19 billion (approximately KRW 29 trillion) in 2024 to USD 23.76 billion in 2025.

“The demand for JAK inhibitors is high, as competing drugs currently available overseas generated sales of USD 580 million last year alone, a 50% increase compared to the previous year,” an 슬롯사이트 inno.N official said. “There is an increasing need to develop topical formulations as an alternative to address the safety and efficacy limitations of existing oral treatments.”

“We aim to offer a broader range of treatment options for atopic dermatitis patients by developing novel 슬롯사이트s that integrate cosmetics and pharmaceutical technologies,” the official further added.

슬롯사이트 inno.N is currently developing a new JAK inhibitor-based autoimmune disease drug for both humans and animals, with atopic dermatitis as the primary indication. The animal drug formulation is being developed as an oral treatment, and the application for the phase 3 clinical trial plan has already been submitted.